Investment Rating - The report maintains a Buy rating for CR Beverage with a target price of HK$11.87, reflecting an 8% decrease from the previous target price of HK$12.85 [1][3]. Core Insights - The forecast for CR Beverage's FY25E net profit is a decline of 35.5% to RMB1.06 billion, with a more significant drop expected in the second half of FY25E due to large marketing contracts and increased supply chain investments [1]. - The company is expected to experience pressure release in 2025, with better growth anticipated during the 15th Five-Year Plan period, potentially starting as early as 2026 [1][9]. - Key positive developments include the appointment of a new Chairman with extensive experience expected to drive significant reforms, particularly in sales [1][9]. - The company is considering increasing its dividend payout ratio in light of weaker performance in 2025 [1][9]. Financial Summary - Revenue for FY25E is projected at RMB11.46 billion, a decrease of 15.2% year-on-year, with a recovery expected in FY26E with 8.3% growth [2][10]. - Net profit for FY25E is expected to be RMB1.06 billion, down from RMB1.64 billion in FY24A, with a recovery to RMB1.29 billion in FY26E [2][10]. - The company's P/E ratio for FY25E is projected at 17.9x, with a decrease in net profit margin to 9.2% [2][10]. Market Position and Share Performance - CR Beverage's market capitalization is approximately HK$24.46 billion, with a current share price of HK$10.20, indicating a potential upside of 16.4% to the target price [3][4]. - The company's packaged water market share has stabilized, showing slight growth at the end of Q3 [9]. - The share performance over the past six months has seen a decline of 21.5% [6].

Report Summary 1. Report Industry Investment Rating - No industry investment rating is provided in the report. 2. Core Viewpoints - The market shows mixed trends across different regions and sectors in the fixed - income market. Some bonds tightened, while others widened or had price changes due to various factors such as demand, profit - taking, and company - specific news [2]. - The analysts maintain a buy rating on BBLTB's subordinated bonds, expecting the bank to call its subordinated bonds on the first call dates due to sufficient capital buffer and past redemption records [7]. 3. Summary by Relevant Catalogs Trading Desk Comments - **Chinese IG Space**: CCAMCL/ORIEAS 2 - 5yr bonds tightened 3 - 5bps due to onshore demand, AMs/prop desks bought FRESHK/ZHOSHK which tightened 1 - 3bps, LIFUNGs gained 0.1 - 0.4pt, EHICAR 26 - 27 were 0.4pt higher [2]. - **Chinese/HK Properties**: ROADKG bonds and perps rose 0.7 - 1.5pts, SHUION 29 gained 0.3pt, FUTLAN 28/LNGFOR 27 - 32s closed 0.5 - 1.2pts higher, VDNWDL/NWDEVL complex were 0.2pt lower to 0.3pt higher, VNKRLE 27 - 29 were 0.3pt higher [2]. - **KR Space**: HYNMTR FRNs tightened 3 - 5bps as onshore/offshore buyers sought loose bonds and dealer inventory dried up [2]. - **JP Space**: NTT 35/MUFG 35s/SOBKCO 35/SMBCAC 35 tightened 1 - 4bps, NOMURA 7 Perp traded 0.1pt lower, RESLIF 6.875 Perp closed 0.1pt higher [2]. - **SE Asia Space**: OCBCSP 32/35s tightened 1 - 3bps, light selling on OCBCSP 34s, KBANK 31/UOBSP 31 - 32s/BBLTB T2s were 1bp tighter to 2bp wider, ReNew Energy complex edged 0.1 - 0.3pt higher, SMCGL Perps/INDYIJ 29s/MEDCIJ 26 - 30s were unchanged to 0.2pt higher, TOPTB 6.1 Perp lost 0.1pt [2]. - **Middle East**: BSFR 35s and long - end KSAs softened 0.1 - 0.3pt lower, SECO 29 - 36s traded active two - way and closed 1 - 2bps wider, ARAMCO 30 - 31s were 1 - 2bps wider, LGFV edged a touch tighter overall [2]. - **Morning Price Movements**: JP AT1s and insurance subs had two - way flows but stable prices, HUXJDP 26 rose 0.9pt, CRNAU 29/HYSAN 4.85 Perp were 0.6 - 0.7pt higher, LNGFOR 28/FTLNHD 27/SOFTBK 31 were 0.5 - 0.8pt lower [3]. Top Performers and Underperformers - **Top Performers**: ROADKG bonds had significant price increases, with ROADKG 6.7 03/30/28 rising 1.5 to 22.9, ROADKG 5 1/8 01/26/30 rising 1.4 to 22.8, etc [4]. - **Top Underperformers**: GARUDA 6 1/2 12/28/31 fell 1.9 to 90.0, ADSEZ 5 08/02/41 fell 1.5 to 87.3, etc [4]. Macro News Recap - Last Friday, S&P was up 0.03%, Dow was down 0.58%, and Nasdaq was up 0.28%. US Jan'26 S&P Global Services PMI was 52.5 (lower than expected), Manufacturing PMI was 51.9 (as expected). UST yield was lower, with 2/5/10/30 - year yields at 3.60%/3.84%/4.24%/4.82% [6]. Desk Analyst Comments on BBLTB - FY25 investment gains offset lower NII and net fee income. Analysts maintain a buy on BBLTB 3.466 09/23/36 and BBLTB 6.056 03/25/40, expecting first - call redemptions [7]. - FY25 results softened: operating profit before tax lowered by 1% to THB56.0bn, net interest income decreased 8% to THB123.6bn, NIM dropped to 2.8% from 3.1% in FY24, net fee income decreased 2% to THB27.2bn, total operating income rose 2% to THB178.5bn, cost - to - income ratio rose slightly to 48.4% [8][9]. - Asset quality deteriorated slightly: NPL ratio increased to 3.0% as of Dec'25 from 2.7% as of Dec'24, NPL coverage ratio decreased to 324% from 334%. However, capital adequacy is solid, with standalone/consolidated CET 1 and Tier 1 ratios increasing [10]. Offshore Asia New Issues - **Priced**: Ma'aden Sukuk Ltd issued USD1000mn 10 - yr bonds with a 5.25% coupon at T + 105, rated Baa1/ - /BBB+ [12]. - **Pipeline**: The Link Finance (Cayman) 2009 plans to issue 10 - yr USD bonds at T + 105, with an issue rating of - /A/ - [13]. News and Market Color - **Onshore Primary Issuances**: 110 credit bonds were issued last Friday with an amount of RMB95bn. Month - to - date, 1,485 credit bonds were issued with a total amount of RMB1,279bn, an 11.1% yoy decrease [17]. - **Company - Specific News**: Adani Energy Solutions plans a USD500mn bond issue, Greenko Energy raised INR48bn (cUSD524mn), Road King sold property interests, Sun Hung Kai settled a tender offer, China Vanke withdrew a REIT listing application and got a loan extension, Yuexiu Property expected FY25 profit to fall 90 - 95% yoy [17].

Market Overview - Global markets showed mixed performance, with the Hang Seng Index closing at 26,750, up 0.45% year-to-date, while the US Dow Jones fell by 0.58% [1][3] - The Chinese stock market saw gains, particularly in materials, consumer discretionary, and healthcare sectors, while energy and real estate lagged [3] Industry Insights - The Chinese pharmaceutical sector is experiencing a significant upward trend, with the MSCI China Healthcare Index rising 9.2% since early 2026, outperforming the MSCI China Index by 5.6% [4] - The trend of Chinese innovative drugs going overseas continues to gain momentum, with multiple business development (BD) transactions occurring in early 2026, indicating a strong market for overseas licensing [5] - Key transactions include the overseas rights granted by Rongchang Biopharma to AbbVie for RC148 and by Haisika for HSK39004, showcasing the clinical progress of these drugs [5] Company Analysis - China Ping An is projected to see a 12% increase in operating profit to RMB 135.9 billion in 2025, driven by improvements in life and health insurance segments [7] - The new business value (NBV) is expected to grow by 42% year-on-year to RMB 40.4 billion, with a strong performance anticipated in the first quarter of 2026, particularly in the bancassurance channel [8] - The target price for China Ping An has been raised to HKD 90, reflecting adjustments in profit and NBV growth forecasts, with the company currently trading at 0.71 times FY26E P/EV [8]

Investment Rating - The report assigns a "Buy" rating to several companies in the pharmaceutical sector, indicating a potential upside of over 15% in their stock prices over the next 12 months [29]. Core Insights - The MSCI China Healthcare Index has increased by 9.2% since the beginning of 2026, outperforming the MSCI China Index, which rose by 5.6% [1]. - The pharmaceutical industry has seen significant growth, driven by strong institutional investor interest and the ongoing trend of innovative drugs going global [1]. - The report emphasizes the importance of clinical progress and data validation for pipelines that have already gone overseas, suggesting that this trend will continue in the long term [1]. Summary by Sections Industry Overview - The report highlights a robust trend in the outbound licensing of innovative drugs, with multiple business development (BD) transactions occurring at the start of 2026, reflecting a high level of activity in the sector [4]. - Key transactions include significant upfront and milestone payments for various drugs, indicating strong market interest and potential for future growth [4]. Company Ratings and Valuations - The report provides detailed valuations for several companies, including: - **Sangfor Technologies (1530 HK)**: Market cap of $7,598.4 million, target price of $37.58, with a 54% upside potential [2]. - **Gusongtang (2273 HK)**: Market cap of $963.3 million, target price of $44.95, with a 46% upside potential [2]. - **WuXi AppTec (2268 HK)**: Market cap of $10,551.0 million, target price of $88.00, with a 28% upside potential [2]. - **China National Pharmaceutical Group (1177 HK)**: Market cap of $15,951.4 million, target price of $9.40, with a 42% upside potential [2]. Market Trends - The report notes that the competition in the PD-(L)1/VEGF space is intensifying, with several companies advancing their clinical trials and aiming for first-line indications [4]. - The report suggests that the efficiency and breadth of clinical trials, as well as the richness of combination therapies, will be critical factors in determining success in this competitive landscape [4].

Investment Rating - The report maintains a "Buy" rating for Ping An Insurance, with a target price raised to HKD 90 based on a sum-of-the-parts (SOTP) valuation [1][4]. Core Insights - The report highlights that the fourth quarter earnings may see relief amid growth stock corrections, with expectations of a 12% year-on-year increase in group OPAT for 2025, reaching RMB 136 billion, and a 5.1% increase in net profit to RMB 133 billion [1][3]. - The insurance company is projected to achieve double-digit growth in NBV (New Business Value) in 2026, driven by strong first-year premium growth and stable profit margins [2][4]. Summary by Sections Financial Performance - For FY25, the net profit is expected to be RMB 162.5 billion, with EPS projected at RMB 7.52, reflecting a 5.1% year-on-year increase [5][13]. - The report provides a detailed financial summary, indicating a steady increase in net profit and EPS over the forecast period, with net profit reaching RMB 175.7 billion by FY27 [5][15]. Valuation Metrics - The target price of HKD 90 implies a valuation of 0.9 times the FY26E price-to-earnings ratio and 1.24 times the price-to-book ratio [4][14]. - The report employs a comprehensive valuation method, indicating a fair value for various segments, including life insurance and property & casualty insurance, contributing to the overall target price [4][14]. Business Growth Drivers - The report notes that the bank's insurance channel is expected to benefit from a shift in household deposits, with a projected 18% growth in NBV for FY26 [2][4]. - The strong performance in the insurance sector is supported by robust underwriting profits and improved investment service results, particularly in the context of a recovering capital market [1][3].

Investment Rating - The report initiates coverage on 康龙化成 with a "Buy" rating and a target price of 38.08 RMB, indicating a potential upside of 21.7% from the current price of 31.30 RMB [1][3]. Core Insights - 康龙化成 is recognized as a leading integrated CXO company in China, established in 2004, providing comprehensive services throughout the drug development lifecycle. The company is expected to benefit from the growing global demand for pharmaceutical R&D outsourcing [1][7]. - The report highlights the company's strategic expansion into various sectors, including small molecule CDMO, clinical development, and large molecule & cell and gene therapy (CGT), which positions 康龙化成 as a competitive player in the global market [7]. - The company is projected to achieve revenue growth rates of 14.2%, 14.8%, and 16.3% for FY25E, FY26E, and FY27E, respectively, with adjusted net profit growth rates of 12.3%, 17.8%, and 18.7% for the same periods [7][11]. Financial Summary - For FY23A, 康龙化成 reported sales revenue of 11,538 million RMB, with a year-on-year growth of 12.4%. The adjusted net profit for the same period was 1,903 million RMB, reflecting a growth of 3.8% [2][11]. - The company’s sales revenue is expected to reach 14,022 million RMB in FY25E, with a projected growth of 14.2% year-on-year [2][11]. - The adjusted net profit is forecasted to be 1,804 million RMB in FY25E, with a year-on-year increase of 12.3% [2][11]. Shareholder Structure - The shareholder structure indicates that 19.3% of the shares are held by Hong Kong investors, while the actual controller holds 17.7% [4]. Stock Performance - The stock has shown a 1-month absolute return of 8.6% and a 6-month return of 15.1%, indicating positive market sentiment [5].

Investment Rating - The report initiates coverage on 康龙化成 (300759 CH) with a "Buy" rating and a target price of 38.08 RMB, indicating a potential upside of 21.7% from the current price of 31.30 RMB [1][3]. Core Insights - 康龙化成 is recognized as a leading integrated CXO service provider in China, benefiting from the growing global demand for pharmaceutical R&D outsourcing. The company offers end-to-end services across the entire drug development lifecycle, positioning itself to capitalize on the increasing outsourcing needs in the pharmaceutical industry [1][7]. - The report highlights the company's strategic expansion into small molecule CDMO, clinical development, and large molecule & cell and gene therapy (CGT) sectors, creating a comprehensive one-stop CXO platform that reduces operational risks and costs for clients [7]. - The company is expected to see revenue growth of 14.2% in 2025, 14.8% in 2026, and 16.3% in 2027, with adjusted net profit growth projected at 12.3%, 17.8%, and 18.7% for the same years [7][8]. Financial Summary - For FY23A, 康龙化成 reported sales revenue of 11,538 million RMB, with a year-on-year growth of 12.4%. The adjusted net profit for the same period was 1,903 million RMB, reflecting a growth of 3.8% [2][11]. - The company’s sales revenue is projected to reach 14,022 million RMB in FY25E, with a corresponding adjusted net profit of 1,804 million RMB, indicating a year-on-year increase of 12.3% [2][11]. - The adjusted earnings per share (EPS) for FY25E is estimated at 1.01 RMB, with a forward P/E ratio of 30.8 times [2][11]. Shareholder Structure - The shareholder structure indicates that 19.3% of the shares are held by Hong Kong investors, while the actual controller holds 17.7% [4]. Stock Performance - The stock has shown a 1-month absolute return of 8.6% and a 6-month return of 15.1%, outperforming the market in these periods [5].

Group 1: Market Overview - Global stock markets showed mixed performance, with the Hang Seng Index closing at 26,630, up 0.17% for the day and 3.90% year-to-date [1] - The Shanghai Composite Index rose by 0.14% to 4,123, while the Shenzhen Composite Index increased by 0.69% to 2,714, reflecting a positive trend in the Chinese market [1] - The US markets also experienced gains, with the Dow Jones up 0.63% and the S&P 500 up 0.55%, indicating a favorable environment for equities [1] Group 2: Sector Performance - In the Hong Kong market, the real estate sector led gains with a 1.62% increase, while the financial sector saw a decline of 0.37% [2] - The energy, real estate, and public utilities sectors in Hong Kong outperformed, while materials, healthcare, and information technology sectors lagged [3] - The A-share market saw significant gains in construction materials, defense, and oil & petrochemicals, while beauty care, banking, and pharmaceuticals underperformed [3] Group 3: Company Analysis - 康龙化成 (300759 CH) - 康龙化成 is recognized as a leading integrated CXO service provider in China, offering comprehensive drug development services [4] - The company is expected to benefit from the growing global demand for pharmaceutical R&D outsourcing, with a target price set at 38.08 RMB and a "buy" rating [4][8] - The company has established a one-stop CXO service platform, significantly reducing operational risks and costs for clients, which is crucial in the current biopharmaceutical landscape [4] Group 4: Business Growth and Projections - 康龙化成's laboratory services are projected to see over 15% growth in new orders in 2024, providing a solid foundation for revenue [5] - The small molecule CDMO segment is expected to grow over 35% in new orders in 2024, driven by commercialized projects [5] - The company anticipates revenue growth of 14.2% in 2025, with non-IFRS net profit expected to increase by 12.3% [8]

Investment Rating - The report maintains a "BUY" rating for iQIYI, indicating a potential return of over 15% over the next 12 months [16]. Core Insights - iQIYI is expected to see a recovery in both revenue and earnings in 4Q25, with total revenue projected to grow by 2% year-over-year (YoY) and 1% quarter-over-quarter (QoQ) to RMB6.77 billion, driven by the recovery of membership and content distribution businesses [1][8]. - The forecast for non-GAAP net income in 4Q25 is RMB93 million, a significant improvement from the non-GAAP net losses recorded in previous quarters [1]. - The target price for iQIYI has been adjusted to US$2.75, based on an 18x multiple of the 2026E non-GAAP EPS, reflecting a 36.8% upside from the current price of US$2.01 [3][11]. Financial Performance Summary - Revenue for FY23A was RMB32,018 million, with a YoY growth of 10.4%. However, FY24A revenue is expected to decline by 8.7% to RMB29,225 million, followed by a further decline of 6.7% in FY25E to RMB27,263 million [2]. - The adjusted net profit for FY23A was RMB2,984.1 million, which is expected to drop to RMB1,512.2 million in FY24A and further to RMB264.1 million in FY25E [2]. - Gross margin is projected to decrease from 27.8% in FY23A to 20.9% in FY25E, before recovering to 23.3% in FY26E and 24.2% in FY27E [2]. Business Forecasts and Valuation - iQIYI's revenue for FY25E is forecasted at RMB27.3 billion, with a slight increase in FY26E to RMB27.9 billion and FY27E to RMB28.4 billion [9]. - The non-GAAP net profit is expected to significantly improve from RMB0.3 billion in FY25E to RMB1.0 billion in FY26E and RMB1.3 billion in FY27E, reflecting a recovery trend [9]. - The valuation of iQIYI is based on a target PE multiple of 18x for 2026E non-GAAP EPS, which is at a discount to the sector average of 24x due to intense competition in the video streaming sector [11].

Group 1: Market Overview - Global markets showed mixed performance, with the Hang Seng Index closing at 26,585, up 0.37% for the day and 3.72% year-to-date [1] - The US markets also experienced gains, with the Dow Jones up 1.21% and the S&P 500 up 1.16% [1] - In contrast, the German DAX and Japanese Nikkei 225 saw declines of 0.58% and 0.41% respectively [1] Group 2: Sector Performance - In the Hong Kong market, the Hang Seng Financial sector fell by 0.44%, while the Hang Seng Utilities sector rose by 1.15% [2] - The real estate sector underperformed, with a decline of 0.77% year-to-date [2] - The industrial sector showed resilience, gaining 0.86% for the day [2] Group 3: Company Insights - iQIYI is projected to see a revenue recovery in Q4 2025, with expected total revenue of RMB 6.77 billion, reflecting a 2% year-on-year growth [4] - The company is anticipated to achieve a non-GAAP net profit of RMB 93 million, a turnaround from previous losses [4] - iQIYI's innovative business segments, including overseas operations and IP derivatives, are showing positive progress [4]